RCT | Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy.

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

Online first: #Sintilimab plus #bevacizumab #biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell #lungcancer #NSCLC who progressed on EGFR TKI therapy: first interim results from ORIENT-31 https://t.co/5VwmLCcGW5 pic.twitter.com/RWeeyfuC6i

— The Lancet Oncology (@TheLancetOncol) August 2, 2022